Browsing Tag
Hong Kong
100 posts
Goodman’s A$19.7bn development book is now 78% data centres as AI demand reshapes the group
Goodman’s development book hit A$19.7bn as data centres reached 78% of WIP, setting up a FY27 test of leasing, funding and AI infrastructure execution.
Lenovo Group Q1 revenue jumps 43% to $26.9bn on AI infrastructure demand
Lenovo Group's Q1 revenue jumped 43% to $26.9bn as ISG nearly doubled and AI sales reached $9.3bn, extending momentum against Dell and HP in AI servers.
HSBC (LSE: HSBA) lifts 2026 income outlook as first-half profit rises 23% to $19.5bn
HSBC Holdings plc has raised its 2026 banking net interest income guidance and resumed share buybacks after stronger lending, deposits and wealth activity lifted first-half earnings. The results were strong, but the bank’s elevated valuation leaves less room for disappointment.
AI chips need optical networks, and Zhongji Innolight is taking that story to Hong Kong
Zhongji Innolight’s US$6.81 billion Hong Kong H-share listing gives investors direct exposure to AI data-centre optical transceivers, but U.S. customer concentration and valuation risk remain central questions.
Typhoon Noul hits southern China as 340,000 evacuate and Hong Kong flights are cancelled
Typhoon Noul hit Guangdong after 340,000 evacuations. Hong Kong flights stopped, but inland flooding may now become the greater danger.
Activeport (ASX: ATV) signs GOIP as Asian telco expansion tests recurring revenue model
Activeport has added GOIP to its expanding Asian telecommunications customer base, strengthening its regional momentum while leaving contract economics and revenue timing as the next investor tests.
Alumasc (AIM: ALU) suspends CEO Pamela Bingham as FY26 profit falls and order book expands
The Alumasc Group plc has suspended Chief Executive Officer Pamela Bingham pending an investigation into matters relating to her professional conduct, less than four months after she assumed the role. The leadership disruption arrived alongside a weaker full-year trading update, leaving investors to weigh a sharply larger order book against falling profit, delayed projects and uncertainty over who will lead the next stage of the company’s recovery plan.
Everest Medicines closes $1.14bn Travere deal for rare kidney disease drug
Everest Medicines closes its $1.14 billion Travere deal for civorebrutinib. Read how the BTK licence reshapes 1952.HK, TVTX and rare kidney strategy.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Nexsen (ASX: NXN) jumps as StrepSure validation path sharpens
Nexsen has FDA pathway momentum and Asia hospital validation. The harder test is whether ASX: NXN can turn StrepSure into revenue.